{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:08:52Z","timestamp":1792789732253,"version":"4.5.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T00:00:00Z","timestamp":1691539200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T00:00:00Z","timestamp":1691539200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Discov."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Systemic administration of Nogo-A-neutralizing antibody ameliorates experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis. However, the blood-brain barrier (BBB) is a major obstacle limiting the passage of systemically applied antibody to the CNS. To bypass the BBB, in the present study we tested the intranasal route of administration by targeting the olfactory mucosa with the Nogo-A-blocking antibody 11C7 mAb in myelin oligodendrocyte glycoprotein-induced EAE. Antibodies were specifically administered onto the olfactory mucosa using a microcatheter. Antibody distribution was examined in the CNS by ELISA and light-sheet microscopy. The effects of 11C7 mAb on Nogo-A signaling were assessed by Western blotting. EAE-induced deficits were monitored daily. Demyelination was observed on spinal cord histological sections. Gene expression changes were followed by trancriptomic analyses. A sensitive capture ELISA revealed a rapid and widespread distribution of 11C7 mAb in the CNS, including the olfactory bulb, the cerebellum and the lumbar spinal cord, but not in the CSF. Light-sheet microscopy allowed to observe antibody accumulation in the parenchyma, thus demonstrating nose-to-brain transfer of IgG. At the functional level, the widespread penetration of 11C7 mAb in the CNS, including the thoracolumbar spinal cord, resulted in the improvement of motor symptoms and in the preservation of myelin in the spinal cord of EAE mice. This was accompanied by Nogo-A signaling downregulation, as reflected by the decreased level of phosphorylated cofilin observed by Western blotting in the cerebellum. In the brain of EAE score-matched animals, 11C7 modified the expression of genes that can influence neurotransmission and cognitive functions, independently of the demyelination phenotype in the spinal cord. In conclusion, our data show the feasibility of olfactory mucosa-directed administration for the delivery of therapeutic antibodies targeting CNS antigens in EAE mice.<\/jats:p>","DOI":"10.1038\/s41420-023-01588-7","type":"journal-article","created":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T13:02:27Z","timestamp":1691586147000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Nogo-A antibody delivery through the olfactory mucosa mitigates experimental autoimmune encephalomyelitis in the mouse CNS"],"prefix":"10.1038","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9618-972X","authenticated-orcid":false,"given":"Vincent","family":"Pernet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Joly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Spiegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivo","family":"Meli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherif","family":"Idriss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Maigler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julius Baya","family":"Mdzomba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna K.","family":"Roenneke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Franceschini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludovico","family":"Silvestri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco S.","family":"Pavone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martino","family":"Calamai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Schindowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,9]]},"reference":[{"key":"1588_CR1","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1056\/NEJMra1401483","volume":"378","author":"DS Reich","year":"2018","unstructured":"Reich DS, Lucchinetti CF, Calabresi PA. Multiple sclerosis. N Engl J Med. 2018;378:169\u201380.","journal-title":"N Engl J Med"},{"key":"1588_CR2","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41582-018-0082-z","volume":"15","author":"M Tintore","year":"2019","unstructured":"Tintore M, Vidal-Jordana A, Sastre-Garriga J. Treatment of multiple sclerosis - success from bench to bedside. Nat Rev Neurol. 2019;15:53\u20138.","journal-title":"Nat Rev Neurol"},{"key":"1588_CR3","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/S1474-4422(20)30140-X","volume":"19","author":"C Lubetzki","year":"2020","unstructured":"Lubetzki C, Zalc B, Williams A, Stadelmann C, Stankoff B. Remyelination in multiple sclerosis: from basic science to clinical translation. Lancet Neurol. 2020;19:678\u201388.","journal-title":"Lancet Neurol"},{"key":"1588_CR4","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00441-012-1432-6","volume":"349","author":"V Pernet","year":"2012","unstructured":"Pernet V, Schwab ME. The role of Nogo-A in axonal plasticity, regrowth and repair. Cell Tissue Res. 2012;349:97\u2013104.","journal-title":"Cell Tissue Res"},{"key":"1588_CR5","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/nrn2936","volume":"11","author":"ME Schwab","year":"2010","unstructured":"Schwab ME. Functions of Nogo proteins and their receptors in the nervous system. Nat Rev Neurosci. 2010;11:799\u2013811.","journal-title":"Nat Rev Neurosci"},{"key":"1588_CR6","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1002\/ana.20627","volume":"58","author":"T Liebscher","year":"2005","unstructured":"Liebscher T, Schnell L, Schnell D, Scholl J, Schneider R, Gullo M, et al. Nogo-A antibody improves regeneration and locomotion of spinal cord-injured rats. Ann Neurol. 2005;58:706\u201319.","journal-title":"Ann Neurol"},{"key":"1588_CR7","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1089\/neu.2011.1752","volume":"29","author":"RR Gonzenbach","year":"2012","unstructured":"Gonzenbach RR, Zoerner B, Schnell L, Weinmann O, Mir AK, Schwab ME. Delayed anti-nogo-a antibody application after spinal cord injury shows progressive loss of responsiveness. J Neurotrauma. 2012;29:567\u201378.","journal-title":"J Neurotrauma"},{"key":"1588_CR8","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1002\/ana.21935","volume":"67","author":"Y Yang","year":"2010","unstructured":"Yang Y, Liu Y, Wei P, Peng H, Winger R, Hussain RZ, et al. Silencing Nogo-A promotes functional recovery in demyelinating disease. Ann Neurol. 2010;67:498\u2013507.","journal-title":"Ann Neurol"},{"key":"1588_CR9","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s00401-017-1745-3","volume":"134","author":"BV Ineichen","year":"2017","unstructured":"Ineichen BV, Kapitza S, Bleul C, Good N, Plattner PS, Seyedsadr MS, et al. Nogo-A antibodies enhance axonal repair and remyelination in neuro-inflammatory and demyelinating pathology. Acta Neuropathol. 2017;134:423\u201340.","journal-title":"Acta Neuropathol"},{"key":"1588_CR10","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1038\/nn1261","volume":"7","author":"T Karnezis","year":"2004","unstructured":"Karnezis T, Mandemakers W, McQualter JL, Zheng B, Ho PP, Jordan KA, et al. The neurite outgrowth inhibitor Nogo A is involved in autoimmune-mediated demyelination. Nat Neurosci. 2004;7:736\u201344.","journal-title":"Nat Neurosci"},{"key":"1588_CR11","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.nbd.2018.11.018","volume":"124","author":"MS Seyedsadr","year":"2019","unstructured":"Seyedsadr MS, Weinmann O, Amorim A, Ineichen BV, Egger M, Mirnajafi-Zadeh J, et al. Inactivation of sphingosine-1-phosphate receptor 2 (S1PR2) decreases demyelination and enhances remyelination in animal models of multiple sclerosis. Neurobiol Dis. 2019;124:189\u2013201.","journal-title":"Neurobiol Dis"},{"key":"1588_CR12","doi-asserted-by":"crossref","first-page":"5393","DOI":"10.1523\/JNEUROSCI.23-13-05393.2003","volume":"23","author":"T Oertle","year":"2003","unstructured":"Oertle T, van der Haar ME, Bandtlow CE, Robeva A, Burfeind P, Buss A, et al. Nogo-A inhibits neurite outgrowth and cell spreading with three discrete regions. J Neurosci. 2003;23:5393\u2013406.","journal-title":"J Neurosci"},{"key":"1588_CR13","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1007\/s13311-020-00864-z","volume":"17","author":"AS Wahl","year":"2020","unstructured":"Wahl AS, Correa D, Imobersteg S, Maurer MA, Kaiser J, Augath MA, et al. Targeting therapeutic antibodies to the CNS: a comparative study of intrathecal, intravenous, and subcutaneous anti-Nogo A antibody treatment after stroke in rats. Neurotherapeutics. 2020;17:1153\u20139.","journal-title":"Neurotherapeutics"},{"key":"1588_CR14","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.bjae.2019.11.002","volume":"20","author":"EM Delhaas","year":"2020","unstructured":"Delhaas EM, Huygen F. Complications associated with intrathecal drug delivery systems. BJA Educ. 2020;20:51\u20137.","journal-title":"BJA Educ"},{"key":"1588_CR15","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.addr.2011.11.002","volume":"64","author":"JJ Lochhead","year":"2012","unstructured":"Lochhead JJ, Thorne RG. Intranasal delivery of biologics to the central nervous system. Adv Drug Deliv Rev. 2012;64:614\u201328.","journal-title":"Adv Drug Deliv Rev"},{"key":"1588_CR16","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.jconrel.2018.08.006","volume":"286","author":"NN Kumar","year":"2018","unstructured":"Kumar NN, Lochhead JJ, Pizzo ME, Nehra G, Boroumand S, Greene G, et al. Delivery of immunoglobulin G antibodies to the rat nervous system following intranasal administration: distribution, dose-response, and mechanisms of delivery. J Control Release. 2018;286:467\u201384.","journal-title":"J Control Release"},{"key":"1588_CR17","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.3390\/pharmaceutics13111904","volume":"13","author":"S Maigler FL","year":"2021","unstructured":"Maigler FL S, Flamm J, G\u00e4nger S, Kurpiers B, Kiderlen S, V\u00f6lk R, et al. Selective CNS targeting and distribution with a refined region-specific intranasal delivery technique via the olfactory mucosa. Pharmaceutics. 2021;13:1904.","journal-title":"Pharmaceutics"},{"key":"1588_CR18","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0022-510X(01)00532-9","volume":"187","author":"XF Liu","year":"2001","unstructured":"Liu XF, Fawcett JR, Thorne RG, DeFor TA, Frey WH 2nd. Intranasal administration of insulin-like growth factor-I bypasses the blood-brain barrier and protects against focal cerebral ischemic damage. J Neurol Sci. 2001;187:91\u201397.","journal-title":"J Neurol Sci"},{"key":"1588_CR19","doi-asserted-by":"crossref","first-page":"12432","DOI":"10.1073\/pnas.192442999","volume":"99","author":"S Capsoni","year":"2002","unstructured":"Capsoni S, Giannotta S, Cattaneo A. Nerve growth factor and galantamine ameliorate early signs of neurodegeneration in anti-nerve growth factor mice. Proc Natl Acad Sci USA. 2002;99:12432\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1588_CR20","doi-asserted-by":"crossref","first-page":"e18296","DOI":"10.1371\/journal.pone.0018296","volume":"6","author":"S Cattepoel","year":"2011","unstructured":"Cattepoel S, Hanenberg M, Kulic L, Nitsch RM. Chronic intranasal treatment with an anti-Abeta(30-42) scFv antibody ameliorates amyloid pathology in a transgenic mouse model of Alzheimer\u2019s disease. PLoS ONE. 2011;6:e18296.","journal-title":"PLoS ONE"},{"key":"1588_CR21","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jneuroim.2004.02.011","volume":"151","author":"TM Ross","year":"2004","unstructured":"Ross TM, Martinez PM, Renner JC, Thorne RG, Hanson LR, Frey WH 2nd. Intranasal administration of interferon beta bypasses the blood-brain barrier to target the central nervous system and cervical lymph nodes: a non-invasive treatment strategy for multiple sclerosis. J Neuroimmunol. 2004;151:66\u201377.","journal-title":"J Neuroimmunol"},{"key":"1588_CR22","doi-asserted-by":"crossref","first-page":"e2200057120","DOI":"10.1073\/pnas.2200057120","volume":"120","author":"D Correa","year":"2023","unstructured":"Correa D, Scheuber MI, Shan H, Weinmann OW, Baumgartner YA, Harten A, et al. Intranasal delivery of full-length anti-Nogo-A antibody: a potential alternative route for therapeutic antibodies to central nervous system targets. Proc Natl Acad Sci USA. 2023;120:e2200057120.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1588_CR23","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41583-019-0250-1","volume":"21","author":"HR Ueda","year":"2020","unstructured":"Ueda HR, Erturk A, Chung K, Gradinaru V, Chedotal A, Tomancak P, et al. Tissue clearing and its applications in neuroscience. Nat Rev Neurosci. 2020;21:61\u201379.","journal-title":"Nat Rev Neurosci"},{"key":"1588_CR24","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1093\/intimm\/dxt044","volume":"26","author":"Y Mori","year":"2014","unstructured":"Mori Y, Murakami M, Arima Y, Zhu D, Terayama Y, Komai Y, et al. Early pathological alterations of lower lumbar cords detected by ultrahigh-field MRI in a mouse multiple sclerosis model. Int Immunol. 2014;26:93\u2013101.","journal-title":"Int Immunol"},{"key":"1588_CR25","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.mcn.2006.03.007","volume":"32","author":"O Weinmann","year":"2006","unstructured":"Weinmann O, Schnell L, Ghosh A, Montani L, Wiessner C, Wannier T, et al. Intrathecally infused antibodies against Nogo-A penetrate the CNS and downregulate the endogenous neurite growth inhibitor Nogo-A. Mol Cell Neurosci. 2006;32:161\u201373.","journal-title":"Mol Cell Neurosci"},{"key":"1588_CR26","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1523\/JNEUROSCI.2806-05.2006","volume":"26","author":"SH Hsieh","year":"2006","unstructured":"Hsieh SH, Ferraro GB, Fournier AE. Myelin-associated inhibitors regulate cofilin phosphorylation and neuronal inhibition through LIM kinase and slingshot phosphatase. J Neurosci. 2006;26:1006\u201315.","journal-title":"J Neurosci"},{"key":"1588_CR27","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-40713-4","volume":"9","author":"R Aharoni","year":"2019","unstructured":"Aharoni R, Schottlender N, Bar-Lev DD, Eilam R, Sela M, Tsoory M, et al. Cognitive impairment in an animal model of multiple sclerosis and its amelioration by glatiramer acetate. Sci Rep. 2019;9:4140.","journal-title":"Sci Rep."},{"key":"1588_CR28","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/nrneurol.2015.222","volume":"11","author":"G Mandolesi","year":"2015","unstructured":"Mandolesi G, Gentile A, Musella A, Fresegna D, De Vito F, Bullitta S, et al. Synaptopathy connects inflammation and neurodegeneration in multiple sclerosis. Nat Rev Neurol. 2015;11:711\u201324.","journal-title":"Nat Rev Neurol"},{"key":"1588_CR29","doi-asserted-by":"crossref","first-page":"13934","DOI":"10.1074\/jbc.M311737200","volume":"279","author":"A Couve","year":"2004","unstructured":"Couve A, Restituito S, Brandon JM, Charles KJ, Bawagan H, Freeman KB, et al. Marlin-1, a novel RNA-binding protein associates with GABA receptors. J Biol Chem. 2004;279:13934\u201343.","journal-title":"J Biol Chem"},{"key":"1588_CR30","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.mcn.2007.04.008","volume":"35","author":"RL Vidal","year":"2007","unstructured":"Vidal RL, Ramirez OA, Sandoval L, Koenig-Robert R, Hartel S, Couve A. Marlin-1 and conventional kinesin link GABAB receptors to the cytoskeleton and regulate receptor transport. Mol Cell Neurosci. 2007;35:501\u201312.","journal-title":"Mol Cell Neurosci"},{"key":"1588_CR31","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1038\/s41593-019-0462-8","volume":"22","author":"ZS Lorsch","year":"2019","unstructured":"Lorsch ZS, Hamilton PJ, Ramakrishnan A, Parise EM, Salery M, Wright WJ, et al. Stress resilience is promoted by a Zfp189-driven transcriptional network in prefrontal cortex. Nat Neurosci. 2019;22:1413\u201323.","journal-title":"Nat Neurosci"},{"key":"1588_CR32","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1083\/jcb.200906089","volume":"188","author":"A Joset","year":"2010","unstructured":"Joset A, Dodd DA, Halegoua S, Schwab ME. Pincher-generated Nogo-A endosomes mediate growth cone collapse and retrograde signaling. J Cell Biol. 2010;188:271\u201385.","journal-title":"J Cell Biol"},{"key":"1588_CR33","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3390\/pharmaceutics10030107","volume":"10","author":"S Ladel","year":"2018","unstructured":"Ladel S, Flamm J, Zadeh AS, Filzwieser D, Walter JC, Schlossbauer P, et al. Allogenic Fc domain-facilitated uptake of IgG in nasal lamina propria: friend or foe for intranasal CNS delivery? Pharmaceutics. 2018;10:107\u201330.","journal-title":"Pharmaceutics"},{"key":"1588_CR34","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.3390\/pharmaceutics12111014","volume":"12","author":"S Ladel","year":"2020","unstructured":"Ladel S, Maigler F, Flamm J, Schlossbauer P, Handl A, Hermann R, et al. Impact of glycosylation and species origin on the uptake and permeation of IgGs through the nasal airway mucosa. Pharmaceutics. 2020;12:1014.","journal-title":"Pharmaceutics"},{"key":"1588_CR35","doi-asserted-by":"crossref","first-page":"6475","DOI":"10.3390\/ijms22126475","volume":"22","author":"M Fieux","year":"2021","unstructured":"Fieux M, Le Quellec S, Bartier S, Coste A, Louis B, Giroudon C, et al. FcRn as a transporter for nasal delivery of biologics: a systematic review. Int J Mol Sci. 2021;22:6475.","journal-title":"Int J Mol Sci"},{"key":"1588_CR36","doi-asserted-by":"crossref","first-page":"5585","DOI":"10.1523\/JNEUROSCI.5705-11.2012","volume":"32","author":"R Fairless","year":"2012","unstructured":"Fairless R, Williams SK, Hoffmann DB, Stojic A, Hochmeister S, Schmitz F, et al. Preclinical retinal neurodegeneration in a model of multiple sclerosis. J Neurosci. 2012;32:5585\u201397.","journal-title":"J Neurosci"},{"key":"1588_CR37","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1002\/ana.410430616","volume":"43","author":"M Filippi","year":"1998","unstructured":"Filippi M, Rocca MA, Martino G, Horsfield MA, Comi G. Magnetization transfer changes in the normal appearing white matter precede the appearance of enhancing lesions in patients with multiple sclerosis. Ann Neurol. 1998;43:809\u201314.","journal-title":"Ann Neurol"},{"key":"1588_CR38","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1212\/WNL.51.6.1689","volume":"51","author":"DE Goodkin","year":"1998","unstructured":"Goodkin DE, Rooney WD, Sloan R, Bacchetti P, Gee L, Vermathen M, et al. A serial study of new MS lesions and the white matter from which they arise. Neurology. 1998;51:1689\u201397.","journal-title":"Neurology"},{"key":"1588_CR39","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1093\/brain\/123.8.1667","volume":"123","author":"DJ Werring","year":"2000","unstructured":"Werring DJ, Brassat D, Droogan AG, Clark CA, Symms MR, Barker GJ, et al. The pathogenesis of lesions and normal-appearing white matter changes in multiple sclerosis: a serial diffusion MRI study. Brain. 2000;123:1667\u201376.","journal-title":"Brain"},{"key":"1588_CR40","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1073\/pnas.1113540109","volume":"109","author":"SY Chong","year":"2012","unstructured":"Chong SY, Rosenberg SS, Fancy SP, Zhao C, Shen YA, Hahn AT, et al. Neurite outgrowth inhibitor Nogo-A establishes spatial segregation and extent of oligodendrocyte myelination. Proc Natl Acad Sci USA. 2012;109:1299\u2013304.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1588_CR41","doi-asserted-by":"crossref","first-page":"e1001763","DOI":"10.1371\/journal.pbio.1001763","volume":"12","author":"A Kempf","year":"2014","unstructured":"Kempf A, Tews B, Arzt ME, Weinmann O, Obermair FJ, Pernet V, et al. The sphingolipid receptor S1PR2 is a receptor for Nogo-a repressing synaptic plasticity. PLoS Biol. 2014;12:e1001763.","journal-title":"PLoS Biol"},{"key":"1588_CR42","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1093\/brain\/aws100","volume":"135","author":"S Petratos","year":"2012","unstructured":"Petratos S, Ozturk E, Azari MF, Kenny R, Lee JY, Magee KA, et al. Limiting multiple sclerosis related axonopathy by blocking Nogo receptor and CRMP-2 phosphorylation. Brain. 2012;135:1794\u2013818.","journal-title":"Brain"},{"key":"1588_CR43","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1080\/09540261.2017.1322555","volume":"29","author":"SB Patten","year":"2017","unstructured":"Patten SB, Marrie RA, Carta MG. Depression in multiple sclerosis. Int Rev Psychiatry. 2017;29:463\u201372.","journal-title":"Int Rev Psychiatry"},{"key":"1588_CR44","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.celrep.2019.09.015","volume":"29","author":"S Fricke","year":"2019","unstructured":"Fricke S, Metzdorf K, Ohm M, Haak S, Heine M, Korte M, et al. Fast regulation of GABAAR diffusion dynamics by Nogo-A signaling. Cell Rep. 2019;29:671\u2013684.e676.","journal-title":"Cell Rep"},{"key":"1588_CR45","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1084\/jem.20020515","volume":"196","author":"ML Hibbs","year":"2002","unstructured":"Hibbs ML, Harder KW, Armes J, Kountouri N, Quilici C, Casagranda F, et al. Sustained activation of Lyn tyrosine kinase in vivo leads to autoimmunity. J Exp Med. 2002;196:1593\u2013604.","journal-title":"J Exp Med"},{"key":"1588_CR46","doi-asserted-by":"crossref","first-page":"789780","DOI":"10.3389\/fphar.2021.789780","volume":"12","author":"JHS Flamm","year":"2021","unstructured":"Flamm JHS, G\u00e4nger S, Maigler F, Schindowski K. Establishment of an olfactory region-specific intranasal delivery techniques in mice to target the central nervous system. Front Pharmacol. 2021;12:789780\u20138.","journal-title":"Front Pharmacol"},{"key":"1588_CR47","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-30533-3","volume":"8","author":"AP Di Giovanna","year":"2018","unstructured":"Di Giovanna AP, Tibo A, Silvestri L, Mullenbroich MC, Costantini I, Allegra Mascaro AL, et al. Whole-brain vasculature reconstruction at the single capillary level. Sci Rep. 2018;8:12573.","journal-title":"Sci Rep"},{"key":"1588_CR48","doi-asserted-by":"crossref","first-page":"041404","DOI":"10.1117\/1.NPh.2.4.041404","volume":"2","author":"MC Mullenbroich","year":"2015","unstructured":"Mullenbroich MC, Silvestri L, Onofri L, Costantini I, Hoff MV, Sacconi L, et al. Comprehensive optical and data management infrastructure for high-throughput light-sheet microscopy of whole mouse brains. Neurophotonics. 2015;2:041404.","journal-title":"Neurophotonics"},{"key":"1588_CR49","unstructured":"R Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2021."},{"key":"1588_CR50","volume":"15","author":"MI Love","year":"2014","unstructured":"Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:550.","journal-title":"Genome Biol"}],"container-title":["Cell Death Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41420-023-01588-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41420-023-01588-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41420-023-01588-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T20:04:32Z","timestamp":1700251472000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41420-023-01588-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,9]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1588"],"URL":"https:\/\/doi.org\/10.1038\/s41420-023-01588-7","relation":{},"ISSN":["2058-7716"],"issn-type":[{"value":"2058-7716","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,9]]},"assertion":[{"value":"4 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Animal experiments were approved by the local authorities (Veterinary Office of the Canton of Bern, Switzerland, licence #BE88\/19).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethic statement"}}],"article-number":"290"}}